Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 5/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S,R)-Mefloquine SCHEMBL32385911 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| (S,R)-Mefloquine SCHEMBL16702641 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| Mefloquine SCHEMBL8575605 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| (R,R)-Mefloquine SCHEMBL21781 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| Mefloquine SCHEMBL17087807 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| (S,S)-Mefloquine SCHEMBL7278974 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| Mefloquine SCHEMBL3625982 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| Mefloquine SCHEMBL21782 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| (S,R)-Mefloquine SCHEMBL21780 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| Mefloquine SCHEMBL29433990 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664397-B1 | Administering to subject effective dose of (+)-mefloquine or pharmaceutically acceptable salt thereof substantially free of (-)-enantiomer; reduced side effects | VERNALIS RESEARCH LIMITED (GB) | 2003-12-16 | — | — | US | claimed |
| EP-0966285-B1 | USE OF (+)MEFLOQUINE FOR THE TREATMENT OF MALARIA | VERNALIS RES LTD (GB) | 2002-10-02 | — | — | EP | claimed |
| US-6197788-B1 | (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders | VERNALIS RESEARCH LIMITED (GB) | 2001-03-06 | — | — | US | claimed |
| US-20160151390-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC. (US) | 2016-06-02 | — | — | US | disclosed |
| EP-3025714-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen MA Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9233107-B2 | Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (PML) | BIOGEN MA INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20130183289-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN IDEC MA INC (US) | 2013-07-18 | — | — | US | disclosed |
| US-6664397-B1 | Administering to subject effective dose of (+)-mefloquine or pharmaceutically acceptable salt thereof substantially free of (-)-enantiomer; reduced side effects | VERNALIS RESEARCH LIMITED (GB) | 2003-12-16 | — | — | US | disclosed |
| US-6664397-B1 | Administering to subject effective dose of (+)-mefloquine or pharmaceutically acceptable salt thereof substantially free of (-)-enantiomer; reduced side effects | VERNALIS RESEARCH LIMITED (GB) | 2003-12-16 | — | — | US | disclosed |
| EP-0966285-B1 | USE OF (+)MEFLOQUINE FOR THE TREATMENT OF MALARIA | VERNALIS RES LTD (GB) | 2002-10-02 | — | — | EP | disclosed |
| EP-0966285-B1 | USE OF (+)MEFLOQUINE FOR THE TREATMENT OF MALARIA | VERNALIS RES LTD (GB) | 2002-10-02 | — | — | EP | disclosed |
| US-6197788-B1 | (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders | VERNALIS RESEARCH LIMITED (GB) | 2001-03-06 | — | — | US | disclosed |
| EP-0966285-A1 | USE OF (+)MEFLOQUINE FOR THE TREATMENT OF MALARIA | Cerebrus Pharmaceuticals Limited (GB) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998039003-A1 | USE OF (+)MEFLOQUINE FOR THE TREATMENT OF MALARIA | CEREBRUS LIMITED (GB) | 1998-09-11 | — | — | WO | disclosed |